# Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression

> **NCT01681446** · PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 296 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** interferon-alpha (IFN-alpha)

## Key facts

- **NCT ID:** NCT01681446
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 296 (ESTIMATED)
- **Last updated:** 2018-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01681446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01681446, "Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01681446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*